Collaboration between Indiana University, Purdue University, Eli Lilly Corporation, and the University of Minnesota

A new research collaboration has been formed between Indiana University, Purdue University, Eli Lilly Corporation, and the University  of Minnesota.  As part of the U of M’s Clinical and Translational Science Institute, the University has committed $150,000 per year for five years (total = $450,000) to this initiative.  Purdue/Indiana and Eli Lilly are contributing equal amounts, for a combined five-year aggregateof $2.25 million.  These funds will support collaborative research with well-chosen animal models with which to test drug-, cell-, and DNA-therapies.  Possible clinical disorders for study could include, but are not limited to, orthopedic disease (e.g., osteoarthritis), cancer (e.g., osteosarcoma, glioma, hemangiosarcoma, lymphoma, TCC), metabolic disorders (e.g., obesity, metabolic syndrome), diabetes mellitus (e.g., types I and II), urology disorders (e.g., FIC, nutritional models), neurologic disorders (e.g., paralysis research, epilepsy models), dermatologic disease (e.g., atopic dermatitis), cardiovascular disease (e.g., medical device intervention), and xenotransplantation (e.g., pancreatic islets).

Deadline: May 3, 2010

Request for proposals

Listing of animal model research at Purdue and UMN